NCT07358650Recruiting
Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma
A Multicenter, First-in-Human Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
It is an interventional study for the treatment of Primary Open-Angle Glaucoma (POAG) using the Hexiris Microinvasive Scleral Trephine (MIST) system. This medical device includes a sclerectomy punch and injector assembly. It is a multicenter, open-label, non-randomized, single-arm study. Adults aged 40 years or more will be enrolled if the POAG is inadequately controlled by topical drug therapies. Only one eye per subject will be treated. The study will be performed on the first five patients in the operating room and the subsequent 20 patients will be treated under a slit-lamp in an aseptic environment (external patient clinic).Once treated with the MIST device, patients will return the next day, 1 week later and 1, 2, 3, 6, 9 and 12 months later. During these follow-up visits, the ophthalmologist will examine the eye and take measurements of the intraocular pressure.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 14 Jan 2026
- Start date
- 15 Jan 2026
- Primary completion date
- 15 Feb 2027
- Lead sponsor
- Hexiris Inc
- Diseases
- Glaucoma
- NCT number
- NCT07358650
What you commit to
- Study type: Interventional
- Planned participants: 25
- From 15 Jan 2026 to the primary completion date, 15 Feb 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior glaucoma filtering surgery (trabeculectomy, shunt or valve) in the treatment quadrant
- Eyes with conjunctival scarring, prior conjunctival surgery or other pathologies in the treatment quadrant
- Patients with uncontrolled bleeding disorders or those receiving anticoagulation therapy without appropriate perioperative management
Other illness
- Active ocular infection or inflammation (e.g. blepharitis, conjunctivitis, keratitis, uveitis).
Lab values
- Women who are (i) pregnant, (ii) nursing, (iii) planning a pregnancy and (iv) of childbearing potential not using a reliable method of contraception as outlined below are excluded:
- Hormonal methods and the intrauterine device (IUD) must be in use at least 30 days prior to first study drug administration
- Barrier methods must be in use at least 14 days prior to study drug administration
- Your male partner vasectomy must be completed 3 months prior to first study drug administration or a sperm count of 0 should be confirmed.
Other
- Angle-closure, neovascular, uveitic, or traumatic glaucoma.
- Eyes with scleral thinning, staphyloma, or structural abnormalities in the treatment quadrant
- Uncontrolled IOP \> 35 mmHg at screening.
- Active or recent (within 6 months) iris neovascularization in the treatment quadrant
- Impaired episcleral venous drainage
- Anterior chamber intraocular lens
- Advanced glaucomatous optic neuropathy.
- Fuchs endothelial dystrophy with clinical signs of endothelial decompensation.
- Central corneal thickness (CCT) \> 600 μm.
- Pathological myopia.
- Patients unable to comply with postoperative follow-up or treatment instructions
Who the study is looking for
- Adults ≥ 40 years with uncontrolled mild to moderate POAG.
- IOP ≥ 18 mmHg on ≥1 topical IOP-lowering medications.
- Open angle on gonioscopy
- Clear cornea and healthy ocular surface
- Capable of giving informed consent, willingness to participate in the trial, and adhering to follow-up
- Glaucomatous visual field loss in one or both eyes at presentation on any of these criteria:
- Reproducible and reliable visual field defects on 2 consecutive fields
- Mild, moderate or advanced disease on mean deviation according to Hodapp classification
- Healthy, mobile conjunctiva in the target quadrant (superior bulbar region)
- Best-corrected Snellen visual acuity of 20/100 or better
- Visual field mean deviation no worse than -18.0 dB (without dense paracentral scotomas)
- No anticipated need for other ocular surgeries (e.g., cataract) within 3 months of post-enrollment
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut de l'oeil des Laurentides Coordinator of this site? Confirm its status | Boisbriand | Canada | Recruiting |
| Prism Eye Institute Inc. Coordinator of this site? Confirm its status | Brampton | Canada | Recruiting |
| Eye Care Centre NB Coordinator of this site? Confirm its status | Dieppe | Canada | Recruiting |
| Miramichi EyeNB & Surgical Centres of Excellence Coordinator of this site? Confirm its status | Miramichi | Canada | Recruiting |
| Ophthalmology Clinic Bellevue Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.